REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB-BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?

Creative Commons License

Demirsoy E. T., GEDÜK A.

TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI, cilt.25, sa.1, ss.58-67, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 1
  • Basım Tarihi: 2022
  • Doi Numarası: 10.31086/tjgeri.2022.263
  • Dergi Adı: TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Scopus, Academic Search Premier, EMBASE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.58-67
  • Anahtar Kelimeler: Multiple Myeloma, Aged, Therapeutics, CYCLOPHOSPHAMIDE, DEXAMETHASONE, CRITERIA, RISK
  • Kocaeli Üniversitesi Adresli: Evet

Özet

Introduction: Elderly patients with multiple myeloma have shorter survival outcomes than younger patients. In this study, we aimed to compare the efficacy and toxicity profiles of conventional and bortezomib-based therapy as first-line therapy in elderly patients with multiple myeloma and to determine the prognostic factors.